ArticleInternational journal of molecular medicine2026
Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression.
Hang Guo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.